Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro

M. Jászberényi, Andrew V. Schally, Norman L. Block, Marta Zarandi, Ren Zhi Cai, Irving Vidaurre, Luca Szalontay, Arumugam R. Jayakumar, Ferenc G. Rick

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Five-year survival of patients afflicted with glioblastoma multiforme (GBM) is rare, making this cancer one of the most feared malignancies. Previously, we reported that growth hormone-releasing hormone (GHRH) is a potent growth factor in cancers. The present work evaluated the effects of two antagonistic analogs of GHRH (MIA-604 and MIA-690) on the proliferation of U-87 MG GBM tumors, in vivo as well as in vitro. Both analogs were administered subcutaneously and dose-dependently inhibited the growth of tumors transplanted into nude mice (127 animals in seven groups). The analogs also inhibited cell proliferation in vitro, decreased cell size, and promoted apoptotic and autophagic processes. Both antagonists stimulated contact inhibition, as indicated by the expression of the E-cadherin-β-catenin complex and integrins, and decreased the release of humoral regulators of glial growth such as FGF, PDGFβ, and TGFβ, as revealed by genomic or proteomic detection methods. The GHRH analogs downregulated other tumor markers (Jun-proto-oncogene, mitogen-activated protein kinase-1, and melanoma cell adhesion molecule), upregulated tumor suppressors (p53, metastasis suppressor-1, nexin, TNF receptor 1A, BCL-2-associated agonist of cell death, and ifκBα), and inhibited the expression of the regulators of angiogenesis and invasion (angiopoetin-1, VEGF, matrix metallopeptidase-1, S100 calcium binding protein A4, and synuclein-γ). Our findings indicate that GHRH antagonists inhibit growth of GBMs by multiple mechanisms and decrease both tumor cell size and number.

Original languageEnglish
Pages (from-to)281-290
Number of pages10
JournalTargeted Oncology
Volume8
Issue number4
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Growth Hormone-Releasing Hormone
Glioblastoma
Neoplasms
Cell Size
CD146 Antigens
Growth
Synucleins
jun Genes
Contact Inhibition
Hormone Antagonists
Catenins
Tumor Necrosis Factor Receptors
Mitogen-Activated Protein Kinase 1
Cadherins
Tumor Biomarkers
In Vitro Techniques
Nude Mice
Integrins
Neuroglia
Proteomics

Keywords

  • Glioblastoma multiforme
  • Growth hormone-releasing hormone
  • Nude mice
  • Targeted therapy
  • U-87 MG

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. / Jászberényi, M.; Schally, Andrew V.; Block, Norman L.; Zarandi, Marta; Cai, Ren Zhi; Vidaurre, Irving; Szalontay, Luca; Jayakumar, Arumugam R.; Rick, Ferenc G.

In: Targeted Oncology, Vol. 8, No. 4, 12.2013, p. 281-290.

Research output: Contribution to journalArticle

Jászberényi, M. ; Schally, Andrew V. ; Block, Norman L. ; Zarandi, Marta ; Cai, Ren Zhi ; Vidaurre, Irving ; Szalontay, Luca ; Jayakumar, Arumugam R. ; Rick, Ferenc G. / Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. In: Targeted Oncology. 2013 ; Vol. 8, No. 4. pp. 281-290.
@article{4a7b8bb617a546cd972a821558d108e3,
title = "Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro",
abstract = "Five-year survival of patients afflicted with glioblastoma multiforme (GBM) is rare, making this cancer one of the most feared malignancies. Previously, we reported that growth hormone-releasing hormone (GHRH) is a potent growth factor in cancers. The present work evaluated the effects of two antagonistic analogs of GHRH (MIA-604 and MIA-690) on the proliferation of U-87 MG GBM tumors, in vivo as well as in vitro. Both analogs were administered subcutaneously and dose-dependently inhibited the growth of tumors transplanted into nude mice (127 animals in seven groups). The analogs also inhibited cell proliferation in vitro, decreased cell size, and promoted apoptotic and autophagic processes. Both antagonists stimulated contact inhibition, as indicated by the expression of the E-cadherin-β-catenin complex and integrins, and decreased the release of humoral regulators of glial growth such as FGF, PDGFβ, and TGFβ, as revealed by genomic or proteomic detection methods. The GHRH analogs downregulated other tumor markers (Jun-proto-oncogene, mitogen-activated protein kinase-1, and melanoma cell adhesion molecule), upregulated tumor suppressors (p53, metastasis suppressor-1, nexin, TNF receptor 1A, BCL-2-associated agonist of cell death, and ifκBα), and inhibited the expression of the regulators of angiogenesis and invasion (angiopoetin-1, VEGF, matrix metallopeptidase-1, S100 calcium binding protein A4, and synuclein-γ). Our findings indicate that GHRH antagonists inhibit growth of GBMs by multiple mechanisms and decrease both tumor cell size and number.",
keywords = "Glioblastoma multiforme, Growth hormone-releasing hormone, Nude mice, Targeted therapy, U-87 MG",
author = "M. J{\'a}szber{\'e}nyi and Schally, {Andrew V.} and Block, {Norman L.} and Marta Zarandi and Cai, {Ren Zhi} and Irving Vidaurre and Luca Szalontay and Jayakumar, {Arumugam R.} and Rick, {Ferenc G.}",
year = "2013",
month = "12",
doi = "10.1007/s11523-013-0264-y",
language = "English",
volume = "8",
pages = "281--290",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro

AU - Jászberényi, M.

AU - Schally, Andrew V.

AU - Block, Norman L.

AU - Zarandi, Marta

AU - Cai, Ren Zhi

AU - Vidaurre, Irving

AU - Szalontay, Luca

AU - Jayakumar, Arumugam R.

AU - Rick, Ferenc G.

PY - 2013/12

Y1 - 2013/12

N2 - Five-year survival of patients afflicted with glioblastoma multiforme (GBM) is rare, making this cancer one of the most feared malignancies. Previously, we reported that growth hormone-releasing hormone (GHRH) is a potent growth factor in cancers. The present work evaluated the effects of two antagonistic analogs of GHRH (MIA-604 and MIA-690) on the proliferation of U-87 MG GBM tumors, in vivo as well as in vitro. Both analogs were administered subcutaneously and dose-dependently inhibited the growth of tumors transplanted into nude mice (127 animals in seven groups). The analogs also inhibited cell proliferation in vitro, decreased cell size, and promoted apoptotic and autophagic processes. Both antagonists stimulated contact inhibition, as indicated by the expression of the E-cadherin-β-catenin complex and integrins, and decreased the release of humoral regulators of glial growth such as FGF, PDGFβ, and TGFβ, as revealed by genomic or proteomic detection methods. The GHRH analogs downregulated other tumor markers (Jun-proto-oncogene, mitogen-activated protein kinase-1, and melanoma cell adhesion molecule), upregulated tumor suppressors (p53, metastasis suppressor-1, nexin, TNF receptor 1A, BCL-2-associated agonist of cell death, and ifκBα), and inhibited the expression of the regulators of angiogenesis and invasion (angiopoetin-1, VEGF, matrix metallopeptidase-1, S100 calcium binding protein A4, and synuclein-γ). Our findings indicate that GHRH antagonists inhibit growth of GBMs by multiple mechanisms and decrease both tumor cell size and number.

AB - Five-year survival of patients afflicted with glioblastoma multiforme (GBM) is rare, making this cancer one of the most feared malignancies. Previously, we reported that growth hormone-releasing hormone (GHRH) is a potent growth factor in cancers. The present work evaluated the effects of two antagonistic analogs of GHRH (MIA-604 and MIA-690) on the proliferation of U-87 MG GBM tumors, in vivo as well as in vitro. Both analogs were administered subcutaneously and dose-dependently inhibited the growth of tumors transplanted into nude mice (127 animals in seven groups). The analogs also inhibited cell proliferation in vitro, decreased cell size, and promoted apoptotic and autophagic processes. Both antagonists stimulated contact inhibition, as indicated by the expression of the E-cadherin-β-catenin complex and integrins, and decreased the release of humoral regulators of glial growth such as FGF, PDGFβ, and TGFβ, as revealed by genomic or proteomic detection methods. The GHRH analogs downregulated other tumor markers (Jun-proto-oncogene, mitogen-activated protein kinase-1, and melanoma cell adhesion molecule), upregulated tumor suppressors (p53, metastasis suppressor-1, nexin, TNF receptor 1A, BCL-2-associated agonist of cell death, and ifκBα), and inhibited the expression of the regulators of angiogenesis and invasion (angiopoetin-1, VEGF, matrix metallopeptidase-1, S100 calcium binding protein A4, and synuclein-γ). Our findings indicate that GHRH antagonists inhibit growth of GBMs by multiple mechanisms and decrease both tumor cell size and number.

KW - Glioblastoma multiforme

KW - Growth hormone-releasing hormone

KW - Nude mice

KW - Targeted therapy

KW - U-87 MG

UR - http://www.scopus.com/inward/record.url?scp=84890568539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890568539&partnerID=8YFLogxK

U2 - 10.1007/s11523-013-0264-y

DO - 10.1007/s11523-013-0264-y

M3 - Article

VL - 8

SP - 281

EP - 290

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 4

ER -